Abstract
BackgroundSevere aortic valve stenosis is one of the most common cause of mortality in adult patients affected with metabolic syndrome, a condition associated with an active inflammatory process involving also mast cells and their mediators, in particular tryptase. The aim of this study was to characterize the possible long-term prognostic role of tryptase in severe aortic valve stenosis.Case presentationThe baseline serum tryptase was measured in 5 consecutive patients admitted to our Hospital to undergo aortic valve replacement for severe acquired stenosis. Within 2 years after, the patients were evaluated for the occurrence of major cardiovascular events (MACE). The tryptase measurements were higher in patients experiencing MACE (10.9, 11.7 and 9.32 ng/ml) than in non-MACE ones (5.69 and 5.58 ng/ml).ConclusionsIn patients affected with severe aortic stenosis, baseline serum tryptase may predict occurence of MACE. Further studies are needed to demonstrate the long-term prognostic role of this biomarker.
Highlights
Severe aortic valve stenosis is one of the most common cause of mortality in adult patients affected with metabolic syndrome, a condition associated with an active inflammatory process involving mast cells and their mediators, in particular tryptase
In patients affected with severe aortic stenosis, baseline serum tryptase may predict occurence of major cardiovascular events (MACE)
Severe aortic valve stenosis is one of the most common cause of mortality in adult patients affected with metabolic syndrome [1], i.e. a clinical condition characterized from visceral obesity that is traduced into insulin resistance, atherogenic dyslipidemia and proinflammatory state [2]
Summary
Severe aortic valve stenosis is one of the most common cause of mortality in adult patients affected with metabolic syndrome, a condition associated with an active inflammatory process involving mast cells and their mediators, in particular tryptase. The aim of this study was to characterize the possible long-term prognostic role of tryptase in severe aortic valve stenosis. Case presentation: The baseline serum tryptase was measured in 5 consecutive patients admitted to our Hospital to undergo aortic valve replacement for severe acquired stenosis. Severe aortic valve stenosis is one of the most common cause of mortality in adult patients affected with metabolic syndrome [1], i.e. a clinical condition characterized from visceral obesity that is traduced into insulin resistance, atherogenic dyslipidemia and proinflammatory state [2]. Severe aortic stenosis is defined by the presence of maximum aortic velocity ≥ 4 m/s, or aortic valve area ≤ 1.0 cm, or by the presence of severe leaflet calcification and severely
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
